4-甲氧基吡啶-2-羧酸肼 | 187973-18-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-甲氧基吡啶-2-羧酸肼
• 英文名称: 4-Methoxypicolinic acid hydrazide
• 英文别名: 4-methoxy-pyridine-2-carboxylic acid hydrazide；4-methoxypicolinohydrazide；4-Methoxy-pyridin-2-carbonsaeure-hydrazid；4-(methyloxy)-2-pyridinecarbohydrazide；4-methoxypyridine-2-carbohydrazide
• CAS: 187973-18-8
• 化学式: C₇H₉N₃O₂
• mdl: MFCD07779513
• 分子量: 167.167
• InChiKey: YKICRDCJQXTGMJ-UHFFFAOYSA-N

物化性质

• 熔点：
  157-159°C
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  77.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P280,P305+P351+P338

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-Methoxy-Pyridine-2-Carboxylic Acid Hydrazide
: ADE000342
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 167,17 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-Methoxy-Pyridine-2-Carboxylic Acid Hydrazide
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-Methoxy-Pyridine-2-Carboxylic Acid Hydrazide
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
No data available
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - No data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲氧基吡啶-2-羧酸肼 在 亚硝酸特丁酯 、 三氟乙酸酐 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 16.5h， 生成 2-氨基-4-甲氧基吡啶
  参考文献：
  名称：

  IMPROVED PROCEDURES FOR PREPARATION OF 4-HYDROXY- AND 2-AMINO-4-METHOXY-2-AMINOPYRIDINES

  摘要：

  DOI：

  10.1080/00304949709355174
• 作为产物：
  描述：

  4-甲氧基吡啶-2-甲酸甲酯 在 一水合肼 作用下， 以 甲醇 为溶剂， 以62%的产率得到4-甲氧基吡啶-2-羧酸肼
  参考文献：
  名称：

  新型席夫碱衍生物和相应的Eu（III）配合物：多种颜色，pH响应机制和荧光性质

  摘要：

  合成对Eu（III）离子具有良好配位能力的有机配体已引起人们的高度重视，然而，在稀土配位领域，制备具有良好性能和潜在应用的多功能有机配体仍然是一个挑战。在这项工作中，我们设计和合成了新型的甲氧基吡啶并肼席夫碱衍生物（MPDS）及其相应的Eu（III）配合物。研究了MPDS在碱性条件下的固态多色发射和pH响应。通过比较不同的取代基，研究了Eu（III）配合物的荧光强度，色纯度和荧光寿命。密度泛函理论（DFT）计算表明，由于水杨醛上取代基的电负性不同，MPDS表现出从绿色到橙色的多种荧光发射，最大发射波长分别为512 nm，534 nm和582 nm。此外，由于分子内电荷转移机制（ICT），MPDS通过在不同线性范围内发出绿色荧光，对pH 7.0–12.0表现出独特的响应。所有络合物均发出具有良好热稳定性和高色纯度的Eu（III）离子出色的红色荧光。有序取代基对Eu（III）配合物的荧光强度和荧光寿命的影响是有序的：[EuL

  DOI：

  10.1016/j.molliq.2020.113071

文献信息

• [EN] 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS<br/>[FR] DÉRIVÉS DE 5,6,7,8-TÉTRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZINE COMME MODULATEURS DE P2X7
  申请人：GLAXO GROUP LTD

  公开号：WO2010125102A1

  公开（公告）日：2010-11-04

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6 R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.

  本发明提供了一种式(I)化合物或其药学上可接受的盐，其中A为氢、C1-4烷基、C3-6环烷基、C1-3烷氧基、C1-3烷氧基C1-4烷基、C1-2氟烷基、卤素、NR6 R7、任选取代的杂芳基(Het)或任选取代的苯基，且R1、R2、R3、R4、R5、R6和R7如说明书中所定义。这些化合物或盐被认为能够调节P2X7受体功能，并能拮抗ATP在P2X7受体上的作用。本发明还提供了该化合物或盐在治疗或预防例如炎症性疼痛、神经性疼痛、内脏疼痛、类风湿性关节炎、骨关节炎或神经退行性疾病中的用途。
• Ｐ２Ｘ７調節Ｎ−アシル−トリアゾロピラジン
  申请人：ヤンセン ファーマシューティカ エヌ．ベー．

  公开号：JP2017527588A

  公开（公告）日：2017-09-21

  本発明は、式（Ｉ）の化合物（そのエナンチオマー及びジアステレオマーを含む）に関する。これらの化合物は、自己免疫・炎症系疾患、神経・神経免疫系疾患、中枢神経系（ＣＮＳ）の神経炎症を伴う疾患及び伴わない疾患又は心血管系、代謝系、胃腸系及び泌尿生殖系の疾患などのＰ２Ｘ７受容体活性に関連する疾患の治療に使用するのに好適である。 【化１】

  该发明涉及式（I）的化合物（包括其手性体和二对映体）。这些化合物适用于治疗与P2X7受体活性相关的自身免疫、炎症性疾病、神经、神经免疫系统疾病、伴有或不伴有中枢神经系统（CNS）神经炎症的疾病，以及心血管系统、代谢系统、胃肠系统和泌尿生殖系统的疾病等。【化1】
• Imidazo-pyridine derivatives as ligands for gaba receptors
  申请人：——

  公开号：US20020188000A1

  公开（公告）日：2002-12-12

  A class of 3-phenylimidazo[1,2-a]pyridine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, are selective ligands for GABA A receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.

  一类3-苯基咪唑并［1,2-a］吡啶衍生物，取代苯环的间位上有一个可选择取代的芳基或杂环基团，该基团直接连接或通过氧原子或—NH—键连接，是GABAA受体的选择性配体，特别是对其α2和/或α3亚单位具有高亲和力，因此对于治疗和/或预防中枢神经系统疾病，包括焦虑和抽搐，具有益处。
• Herbicidal acylhydrazides
  申请人：BASF SE

  公开号：EP2371219A1

  公开（公告）日：2011-10-05

  The present invention relates to a method for controlling undesired vegetation by application of acylhydrazides of the general formula I wherein the variables are defined according to the description, processes and intermediates for preparing the acylhydrazides of the formula I, compositions comprising them and their use as herbicides, i.e. for controlling harmful plants, a method for controlling unwanted vegetation which comprises allowing a herbicidal effective amount of at least one acylhydrazide of the formula I to act on plants, their seed and/or their habitat as well as to their use as pharmaceutical active compound and a method of treating or preventing infections by application of the acylhydrazides of the formula I.

  本发明涉及一种通过应用通式I的酰基脒类化合物来控制不受欢迎的植被的方法，其中变量根据说明书中的定义确定，用于制备通式I的酰基脒类化合物的工艺和中间体，包含它们的组合物以及它们作为除草剂的用途，即用于控制有害植物的方法，一种控制不受欢迎植被的方法，包括让至少一种通式I的酰基脒类化合物在植物、它们的种子和/或它们的栖息地上发挥除草有效作用，以及它们作为药用活性化合物的用途以及通过应用通式I的酰基脒类化合物来治疗或预防感染的方法。
• TRIAZOLE AGONISTS OF THE APJ RECEPTOR
  申请人：AMGEN INC.

  公开号：US20170044131A1

  公开（公告）日：2017-02-16

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用可接受的盐，任何上述的立体异构体，或其混合物均为APJ受体激动剂，并可用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构：其中变量的定义在此处提供。